UNSPSC 51323101: Anisacril

This classification denotes an anti-lipidemic agent and anorexiant with the molecular formula C22H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5TB1FV429Z, chemically known as 2-propenoic acid, 3,3-diphenyl-2-(o-methoxyphenyl)- but generally known as anisacril, which bears US NIH Compound Identifier 21203. European Medicines Agency schedules Anisacril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05519MIG. The term ANISACRIL is an International Non-Proprietary Name.

UNSPSC 51323101 Anisacril is a Commodity code under which state and local governments procure injectable emergency medications and pharmaceutical products for clinical use. Recent solicitations show that state agencies, cities, and cooperative purchasing alliances are actively acquiring specific branded and generic medications—including epinephrine, labetalol, adenosine, diltiazem, and broader pharmaceutical inventories—for fire rescue services, health agency programs, and multi-jurisdictional distribution networks. The work encompasses direct procurement of finished pharmaceutical goods with specified expiration-date requirements, pharmaceutical compliance certifications (cGMP, DSCSA, FDA), Safety Data Sheets and accessibility documentation, and vendor responsibility for inventory management, product warranties, and timely delivery.

Activity under the code spans multiple issuing-body types: the City of Tampa's Purchasing Department (fire rescue medications), the Texas Health and Human Services Commission (pharmacy benefit program research), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which aggregates demand across state and local facilities including Oregon. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications with a due date of April 8, 2026, and an estimated contract value of $40,000.00, seeking four specific injectable medications for Tampa Fire Rescue with a one-year term and two one-year renewal options. MMCAP issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, for a two-year term effective July 1, 2026, requiring vendors to supply through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and certify cGMP and DSCSA compliance. Texas HHS issued RFI HHS0017013 in March 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs as a preliminary market-intelligence phase before formal RFP issuance. Geographic spread includes Florida, Texas, and the Upper Midwest (Minnesota and Oregon via MMCAP); the MMCAP vehicle indicates multi-state cooperative purchasing reach.